Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

<< Previous

Bullboard Posts

Next >>

Post by narmacon Dec 22, 2021 11:36am

213 Views

Post# 34254612

OTC short interest on RVXCF.

SHORT INTEREST

DATE	SHORT INTEREST	% CHANGE	AVG. DAILY SHARE VOL	DAYS TO COVER	SPLIT	NEW ISSUE
11/30/2021	664,922	3.55	76,697	8.67	No	No
11/15/2021	642,099	6.67	96,238	6.67	No	No
10/29/2021	601,975	60.21	27,190	22.14	No	No
10/15/2021	375,738	4.46	27,139	13.84	No	No
09/30/2021	359,691	2.95	26,933	13.36	No	No
09/15/2021	349,382	-5.18	37,015	9.44	No	No
08/31/2021	368,479	3.37	17,636	20.89	No	No
08/13/2021	356,474	1.09	18,718	19.04	No	No
07/30/2021	352,644	6.23	38,075	9.26	No	No
07/15/2021	331,976	3.67	17,426	19.05	No	No